Top Tech Companies (83)
Don't see your company?
Create a company profile
Biofourmis is a fast-growing digital health company filled with committed, passionate people who care about augmenting personalized care and empowering people with complex chronic conditions to live better and healthier lives. We are pioneering an entirely new category of medicine, by developing clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Biofourmis has built Biovitals®, a highly sophisticated personalized AI-powered health analytics platform that predicts clinical exacerbation in advance of a critical event, which is the backbone of their digital therapeutics’ product pipeline across multiple therapeutic areas—including heart failure, oncology, acute coronary syndrome, COPD and chronic pain.
Strand was started by biological engineers working together at MIT. Building on the idea of creating smart therapies that are capable of making sophisticated decisions, they sought to apply the concept of the emerging field of mRNA therapeutics. This area was untapped by traditional synthetic biology, which led them to build their own mRNA “programming language,” creating the world’s first platform for mRNA smart therapies. Strand’s mRNA programming technology promises to make mRNA therapies safer and more effective by programming the location, timing, and intensity of therapeutic protein expression inside a patient’s body using mRNA-encoded logic circuits. These circuits can implement cell-type specific expression by sensing and classifying the unique miRNA expression signatures of cells, as well as controlling the dosage of protein expression by responding to exogenously administered small molecules.
When two architects from Zaha Hadid’s research lab first approached robotics, their idea was to explore applications specific to architectural engineering. But they soon discovered that modern automation wasn’t just unnecessarily complex – it was actively restricting innovation. And not just within their industry – in many others too. It was clear that robotic automation was a field where their combined experience in computational research and design could make a real difference. Assembling a team of industry experts, Automata was founded with a clear aim: to enable new opportunities for innovation with automation.
At Nimbus, we design breakthrough medicines. Utilizing our powerful structure-based drug discovery engine, we create potent and selective small molecule compounds targeting proteins that are known to be fundamental drivers of pathology in highly prevalent human diseases and which have proven difficult for other drug makers to tackle. With a decade-plus track record of success, we’ve built a world-class team in both computationally driven drug discovery and early clinical development while continuing to move the needle for patients.
At Odyssey, we are creating next generation precision medicines for patients with cancer and inflammatory diseases with class-leading speed, efficiency and rigor through our highly integrated drug hunting engine.
Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic diseases, with an initial focus on neuromuscular diseases.
PF is a consulting firm providing biomanufacturing strategy and execution. Our services include turnkey capital projects and facility builds; owner's representation and program/project management; validation; quality, regulatory and compliance; engineering and automation and more. We partner with startup and established pharmaceutical companies, advanced therapy companies, academia, hospitals, financial institutions, and CROs/CMOs. One of our core values is giving back. Volunteering at hospitals, supporting healthcare-related fundraisers and partnering with nonprofit organizations is an integral part of our culture. In doing so, not only do we raise awareness of many life-threatening diseases, but we also bring our team and our client’s team closer to the actual patients and families that will be impacted by our work. Project Farma is a Precision for Medicine company and part of Precision ADVANCE, the cell & gene therapy collective™ (https://www.precisionmedicinegrp.com/advance/)
inviCRO is an image science company that provides advanced data analysis services and software in the growing field of pre-clinical imaging research. In collaboration with partner imaging centers, inviCRO facilitates full-service contract research imaging services utilizing SPECT, PET, MR, CT and Optical imaging technologies. To this effort, inviCRO has developed a product line of dedicated analysis and software services addressing image processing and reporting required of a pre-clinical laboratory running imaging trials.
At PathAI our mission is to improve patient outcomes with AI-powered technology. PathAI’s platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine and deep learning.
Eurofins Scientific is an international life sciences company, providing a unique range of analytical testing services to clients across multiple industries, to make life and the environment safer, healthier and more sustainable. From the food you eat to the medicines you rely on, Eurofins works with the biggest companies in the world to ensure the products they supply are safe, their ingredients are authentic and labelling is accurate. Eurofins is a global leader in food, environmental, pharmaceutical and cosmetic product testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In over just 30 years, Eurofins has grown from one laboratory in Nantes, France to over 61,000 staff across a network of over 1,000 independent companies in 59 countries, operating 940 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Eurofins is one of the fastest growing listed European companies. Since its IPO on the French stock exchange in 1997, Eurofins’ revenues have increased by 33% each year (in compound average) to reach €6.7 billion in 2021.
Landmark Bio is a collective endeavor launched by leaders from academia, the life sciences industry, and world-renowned research hospitals to accelerate development and industrialization of next-generation genomic medicine. Inspired by recent advancements in cell and gene therapy, Landmark Bio was established to remove barriers in drug development, create accessible capability, expertise, and solutions, and offer a collaboration platform to advance manufacturing technologies for the new generation of medicines to come. Founding partners include Harvard University, Massachusetts Institute of Technology (MIT), Cytiva, FUJIFILM Diosynth Biotechnologies (FDB), and Alexandria Real Estate Equities, Inc. Other collaborating institutions include Beth Israel Deaconess Medical Center, Boston Children’s Hospital, Mass General Brigham, and the Dana-Farber Cancer Institute. For more information please contact [email protected]
We are a life sciences company that is building on over a decade of extensive research on the genetic mutations associated with cystic fibrosis. We are developing first-in-class small molecules that are focused on a unique target with the potential to fully normalize CFTR function for the first time for the vast majority of people living with CF.
Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide.
BioRAFT designs enterprise level SaaS based software to mitigate risk for laboratory researchers and Environmental Health and Safety (EH&S) professionals. Our management, product development, customer success and sales teams come from academic and pharmaceutical research, scientific software, education, EH&S, healthcare, and aerospace industries.
Dyno Therapeutics is pioneering an artificial intelligence (AI) powered approach to gene therapy. Using machine learning and quantitative high-throughput in vivo experimentation, we are inventing new ways to design gene vectors with a focus on cell-targeting capsid proteins from adeno-associated virus (AAV), the most widely-used vector for gene therapies. Our team includes world-class molecular and synthetic biologists, protein engineers and gene therapy scientists working alongside software engineers, data scientists, and AI and machine learning experts. As we create AI-powered gene therapies that enhance the life-changing potential of gene therapies for millions of patients, we believe the future is within reach. Gene vectors are the key for enabling gene therapies to reach a wider range of diseases and patients. Success in gene therapy relies on the vector’s ability to safely and precisely deliver a gene payload to the intended target cells and tissues. The efficacy of gene therapies, however, is currently limited by the roster of naturally occurring vectors, which are not optimized for disease treatment. To solve this problem and realize the full potential of gene therapy, Dyno is building its portfolio of proprietary AAV vectors, and working with licensing partners to build targeted AAV vectors enabling treatments in a wide range of disease areas and indications.
Reverie Labs is a pharmaceutical company that uses its innovative computational chemistry and machine learning tools to accelerate its drug discovery programs. Reverie's primary goal is to develop kinase inhibitors that address the unmet needs of patients.
Volta Labs is a collective of antidisciplinary scientists and builders working at the intersection of engineering and biology. Our mission is clear: unlock the utility of genomics for the world. To do this, we’re building a sequencing technology agnostic platform that revolutionizes the entire sample prep process — from raw biological samples to sequenceable molecules. This makes an imagined world in which a single instrument automates the majority of biological workflows done in a lab into a reality. Our platform can handle a wide range of raw biological samples and deliver sequenceable molecules - all at the push of a button. This has required reinventing the full stack of technologies – hardware, software, chemistry, and biology.
Matterworks is developing advanced AI-powered software and proprietary chemistry reagents to enable real-time, quantitative metabolomics to accelerate the research, development, and manufacturing of biologic therapeutics. Metabolomics measures all the small molecules a cell needs to function. In spite of its far-reaching potential impact across life science disciplines, adoption of metabolomics remains limited and lags behind other ‘omic techniques due to a number of inherent challenges. Matterworks is developing a novel alternative methodology that activates deep learning (DL) for analytical chemistry, to remove the constraints imposed by the requirement for human-interpretable data. Matterworks is on a mission to democratize metabolomics and catalyze its widespread adoption and integration into the life sciences. Our view is very simple: solving metabolomics will advance all of the life sciences industries.
Headquartered in Boston’s Seaport community, Entrada Therapeutics is a growing biopharmaceutical company innovating to transform the treatment of devastating diseases through intracellular therapeutics. We’re establishing a new class of medicines, Endosomal Escape Vehicles (EEV™), with the potential to engage intracellular targets that have long been considered inaccessible and undruggable. Our EEV™ therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through our proprietary, highly versatile, and modular EEV™ Platform, we are building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular diseases, immunology, oncology, and diseases of the central nervous system. For more information about Entrada, please visit www.entradatx.com.
nirrin is developing sensors and analytics to enable the next generation of biological manufacturing. Using near-infrared spectroscopy we are able to attain real-time, reliable measurements of critical bioprocess parameters. We are primarily focused on applications within the biopharma industry however our technology has the potential to be used across the life sciences. Our small but passionate team is currently working on integrating novel near-infrared sensors with other data sources to provide process control for cell culture. We are looking for a developer with a strong design background to work with the engineering team on the next generation user interface for our data acquisition and analytics software.
